Collect Clinical Data in Chinese Patients Received CUBICIN Treatment for Actual Usage in Clinical Practice

Completed

• Conditions: S. Aureus Bloodstream Infection

• Registration Number: NCT01212601
• Lead Sponsor: AstraZeneca

Brief Summary

This is a Multicenter, observational, non-interventional registry designed to collect clinical data in Chinese patients who have received CUBICIN treatment under condition of actual usage in clinical practice.

Detailed Description

MC MD

Study Timeline

• Study First Submitted: 2010-09-16
• Study First Submitted QC: 2010-09-29
• Study First Posted: 2010-09-30
• Study Start: 2011-01
• Status Verified: 2012-11
• Primary Completion: 2012-11
• Study Completion: 2012-11
• Last Update Submitted: 2012-11-23
• Last Update Posted: 2012-11-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 203

Inclusion Criteria

• Patient has received CUBICIN treatment, decided by treating physician
• A patient who is considered as ethnic Chinese
• Provision of subject informed consent

Exclusion Criteria

• A patient record will not be eligible for the registry database if the patient received CUBICIN as part of a controlled clinical study for the current infection episode.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
AEs of CUBICIN therapy	2 weeks
clinical response of CUBICIN therapy at each available time point	2 weeks

Secondary Outcome Measures

Name	Time	Method
CPK level monitoring and results	2 weeks
treatment duration	2 weeks
Time to clinical response	2 weeks

Trial Locations

Locations (1)

Research Site; 🇨🇳 Kunming, Yunnan, China